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The concept that cell death can be a regulated process 
under molecular control is now well established. Much 
evidence also indicates that the molecular machinery for 
death has been well conserved through evolution. Until 
recently, efforts to identify components of this machinery 
were focused primarily on identifying endonucleases ca- 
pable of cleaving DNA at internucleosomal sites, since 
this type of DNA degradation is a well-established charac- 
teristic of most, but not all, forms of apoptosis. However, 
observations from studies using enucleated cells as well 
as cell-free systems indicate that the central components 
of the cell death machinery, which we will call the execu- 
tioner, are most likely localized to the cytosol. Further- 
more, several lines of evidence indicate that proteases, 
particularly those of the emerging interleukin-lp (IL-lp)- 
converting enzyme (ICE) family, are good candidates for 
regulators or components (or both) of the executioner. 
Proteolysis and Apoptosis 
One of the early indications that proteases could be im- 
portant triggers for apoptosis came from studies on pro- 
teins found in the cytoplasmic granules of cytotoxic T lym- 
phocytes and natural killer cells, both of which kill by 
binding to target cells and inducing apoptosis within--the 
so-called kiss of death. Purification of the constituents of 
cytotoxic T lymphocyte and natural killer granules yielded 
perforin, a pore-forming protein, as well as a series of ser- 
ine proteases, one of which, granzyme B/fragmentin-2, 
has the unusual property of cleaving at Asp residues (Shi 
et al., 1992). Exposure of target cells to purified prepara- 
tions of perforin/granzyme B in combination was sufficient 
to induce apoptosis. 
More direct evidence that proteases may be centrally 
involved in the regulation of the cell death process has 
come from studies on the nematode Caenorhabditis ele- 
gans. A series of genes that control various elements of the 
programmed cell death process in this worm have been 
identified, two of which, ced-3 and ced-4, are required for 
cell death during development. Subsequently, ced-3 was 
found to exhibit significant homology to Ice (Yuan et al., 
1993), which converts the 33 kDa protease form of IL-113 
to the active 17.5 kDa form, once again by cleaving after 
Asp residues (Thornberry et al., 1992). Ectopic expression 
of Ice in fibroblasts resulted in apoptosis, suggesting that 
Ice is both functionally as well as structurally homologous 
to ced-3 (Miura et al., 1993). These observations have 
been closely followed by the discovery of several more 
Ioe/ced-3 homologs: Nedd-2/Ich-1 (Kumar et al., 1994; 
Wang et al., 1994), CPP32/Yama (Fernandes-Alnemri et 
al., 1994; Tewari et al., 1995), Tx/Ich-2 (Faucheu et al., 
1995; Kamens et al., 1995), and Mch-2 (Fernandes- 
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Alnemri et al., 1995) in which the pentameric peptide, 
QACRG, surrounding the putative actived site Cys, is com- 
pletely conserved (Table 1). As with ICE, overexpression 
of each of these proteases in various cell types results in 
apoptosis. 
A third line of evidence for a role for proteases in apoptosis 
comes from studies that have explored the effects of di- 
verse protease inhibitors on apoptosis induced by a variety 
of agents. These studies have implicated calpain I, a cal- 
cium-dependent protease, in activation-induced apoptosis 
(Sarin et al., 1993), as well as apoptosis induced by dexa- 
methasone, low level irradiation, or macromolecular syn- 
thesis inhibition (Squier et al., 1994). 
In addition, a number of proteins, including but not re- 
stricted to poly(ADP-ribose) polymerase (PARP) (Kauf- 
mann et al., 1993; Lazebnik et al., 1994), the 70 kDa pro- 
tein component of the U1 small nuclear ribonucleoprotein 
(Casciola-Rosen et al., 1994), lamin B1 (Neamati et al., 
1995; VoelkeI-Johnson et al., 1995; Lazebnik et al., 1995), 
~-fodrin (Martin et al., 1995), topoisomerase I (Voelkel- 
Johnson et al., 1995), and ~-actin (Kayalar et al., 1995), 
have been reported to become degraded in association 
with the onset of apoptosis, thereby providing direct evi- 
dence for the activation of one or more proteases during 
this process. 
Proteases as Components of the Executioner 
The observation that overexpression of ICE or its homo- 
logs results in apoptosis may not be all that significant by 
itself, particularly given the fact that introduction of practi- 
cally any protease into cells in a deregulated manner is 
likely to provoke considerable damage and result in cell 
death. This is illustrated by studies in which delivery of 
either chymotrypsin, proteinase K, or trypsin into the cyto- 
plasm of several different cell types resulted in apoptosis 
within a few hours (Williams and Henkart, 1994). 
More direct evidence that ICE, an ICE-like protease, or 
both are required for apoptosis stems from studies that 
have explored the effects on apoptosis of CrmA, an inhibi- 
tor of ICE encoded by the cowpox virus, or specific tetra- 
peptide (YVAD) ICE inhibitors. For example, CrmA- 
expressing Rat1 fibroblasts were protected from death 
owing to serum withdrawal (Wang et al., 1994). Overex- 
pression of crmA also prevented apoptosis due to engage- 
ment of the Fas (CD95) receptor or to exposure to tumor 
necrosis factor ~ (Tewari and Dixit, 1995; Enari et al., 1995; 
Table 1. ICE Family Proteases Implicated in Apoptosis 
Protease Active S i te  Substrates 
ICE QACRG Pro-II-1 p, pro-ICE, 
pro-YAMA 
CED-3 QACRG ? 
ICH-1/NEDD-2 QACRG ? 
CPP32/YAMA QACRG PARP 
TX/ICH-2 QACRG Pro-ICE, pro-TX 
MCH-2 QACRG PARP 
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Los et al., 1995). In line with these observations, tetrapep- 
tide inhibitors of ICE activity dramatically inhibited cell 
death due to Fas ligation (Enari et al., 1995; Los et al., 
1995). In addition, rapid increases in ICE or ICE-like activ- 
ity are observed within minutes of engagement of Fas (Los 
et al., 1995). 
Further evidence for the involvement of an ICE-like pro- 
tease in apoptosis comes from studies on the short form 
of the Ice/ced-3 homolog Ich-1/Nedd-2. Whereas the long 
form of Ich-l, Ich-lL, induced apoptosis of Rat1 fibro- 
blasts, overexpression of Ich-lS actually suppressed se- 
rum withdrawal-induced apoptosis in the same cells 
(Wang et al., 1994). This suggests either that ICH-1S com- 
petes for the same downstream targets of ICH-1L or other 
ICE-like proteases but does not cleave them or that ICH-1 S 
somehow inactivates the proteases themselves, possibly 
by becoming incorporated into oligomeric complexes with 
full-length forms of ICH-1 or other ICE family proteases 
(Gu et al., 1995). 
It has also recently been demonstrated that cleavage 
of PARP, one of the proteins known to be cleaved in associ- 
ation with apoptosis, can be catalysed by CPP32/YAMA, 
an ICE-like protease (Tewari et al., 1995; Fernandes- 
Alnemri et al., 1995). This cleavage was prevented by 
CrmA, both in intact cells as well as in vitro, whereas a 
CrmA point mutant that had lost the ability to interact with 
CPP32/YAMA as well as ICE was ineffective in this regard 
(Tewari et al., 1995). These observations are important 
since they not only identify an ICE homolog as being re- 
sponsible for proteolysis of a protein known to be degraded 
during apoptosis, but they also raise the possibility that 
CrmA blocks apoptosis in the cases mentioned earlier, not 
by neutralizing ICE, but by utilizing its ability to neutralize 
CPP32/YAMA or other ICE-like proteases. Similar conclu- 
sions could also be drawn regarding the YVAD inhibitor 
studies described above. In this context, it is also interest- 
ing to note that whereas ICE is capable of processing 
CPP32/YAMA to its active form, the reverse is not true 
(Tewari et al., 1995). It is therefore tempting to speculate 
that in studies in which ectopic expression of ICE resulted 
in apoptosis (Miura et al., 1993), this may have been due 
to activation of CPP32/YAMA in these cells. 
Recent data derived from Ice knockout mice would seem 
to suggest that ICE itself is not an essential requirement 
for cell death, except perhaps for Fas-related apoptosis of 
thymocytes (Kuida et al., 1995), since these mice develop 
normally and cells from these animals are capable of un- 
dergoing apoptosis in vitro (Li et al., 1995; Kuida et al., 
1995). The fact that several ICE homologs, with overlap- 
ping tissue distribution, are now known to exist suggests 
that either there is redundancy in the executioner or that 
an ICE-like protease such as CPP32/YAMA or TX/ICH-2, 
rather than ICE itself, is more centrally involved in the cell 
death process. 
How Does Proteolysis Lead to the Stereotypic 
Changes Associated with Apoptosis? 
Although apoptosis was described almost 25 years ago, 
it is remarkable that we still know so little concerning the 
mechanistic aspects of the most dramatic features of this 
process--condensation of the nucleus, degradation of the 
chromatin, and pronounced blebbing of the plasma mem- 
brane. One particularly attractive feature of the idea that 
proteases could be key components of the executioner is 
that it is relatively easy to conceive how activation of one 
or more proteases could directly produce at least some 
of the structural changes seen during apoptosis. A scheme 
showing known and hypothetical roles for proteases in 
apoptosis is shown in Figure 1. 
Activation of a protease can lead to processing and acti- 
vation of additional molecules of the same or other pro- 
teases, leading to an amplified protease cascade. This is 
a common theme in protease function, and such protease 
cascades are central to the processes of clotting and com- 
plement activation. Among the proteases associated with 
apoptosis, at least three are known to interact in this way. 
Thus, TX/ICH-2 can process both pro-TX and pro-ICE 
(Faucheu et al., 1995), and ICE processes both pro-ICE 
and pro-YAMA/CPP32 (Thornberry et al., 1992; Tewari et 
al., 1995). It is also possible that the activation of these or 
related proteases contributes to the activation of another 
protease, calpain, that is often induced during apoptosis 
(Sarin et al., 1993; Squier et al., 1994; Martin et al., 1995). 
The result may be an escalating cascade of proteases. 
Proteolytic cleavage of specific substrates may further 
contribute to the process of apoptosis in several ways: 
through structural changes, by activation of other effector 
molecules such as nucleases (e.g., processing of pro- 
forms of a protein), or by removal of an inhibitor (by analogy 
with degradation of h<B to release NF-KB). Some of the 
effects would be expected to be cell type specific, if a 
relevant substrate were expressed in a tissue-specific 
~tc.) 
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Figure 1. Proteases as Central Components of the Executioner 
Summarized are known (solid lines) and putative (broken lines) interac- 
tions between proteases and their subetrates that take place during 
apoptosis. The central box places the known ICE family proteases 
within the executioner. Although some of these proteases are known 
to interact, here is currently no evidence that they act as a complex. 
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manner. Since apoptosis tends to be morphologically simi- 
lar among different cells, we would predict that the most 
important substrates are fairly ubiquitous and are evolu- 
tionary conserved, at least at their cleavage sites. 
Relatively few targets for proteolysis during apoptosis 
have been identified. Some of these fit the above predic- 
tions and might have important roles in apoptosis. At this 
time, however, the role of these substrates in apoptosis 
remains largely hypothetical. 
Some of the most characteristic hanges associated 
with apoptosis affect the nucleus, and proteolysis could 
play a major role here. For example, lamin B1 degradation 
during apoptosis could lead to collapse of the chromatin 
due to the loss of attachment points on the nuclear matrix 
(Neamati et al., 1995). Recent observations uggest that 
an ICE-like protease, distinct from the PARP-cleaving pro- 
tease CPP32/YAMA, is responsible for degradation of the 
lamins during apoptosis (Lazebnik et al., 1995). Interest- 
ingly, while inhibition of lamin-cleaving protease activity 
does not interfere with chromatin margination or DNA deg- 
radation, it does prevent he collapse of the chromatin into 
discrete blobs and break-up of the nucleus that typifies 
late stage apoptosis (Lazebnik et al., 1995). It is also possi- 
ble that proteases could contribute to DNA'fragmentation 
by activation of endonucleases; a partially characterized 
24 kDa protease has been shown to induce the formation 
of characteristic DNA ladders when added to isolated nu- 
clei, but this protease does not itself exhibit any nuclease 
activity (Wright et al., 1994). In addition, the cleavage of 
PARP by CPP32/YAMA or MCH-2 (Tewari et al., 1995; 
Fernandes-Alnemri et al., 1995) inhibits most of its DNA 
repair activity (Kaufmann et al., 1993), and this may also 
contribute to the demise of the cell. 
Other characteristic hanges during apoptosis focus on 
the plasma membrane and cytoskeleton, as cells lose ad- 
herence, bleb, and fragment. Adherent cells can be readily 
removed from the substratum by limited proteolysis, and 
it is not unlikely that this is what happens when such cells 
undergo apoptosis. Blebbing and cellular fragmentation 
into apoptotic bodies depend upon actin polymerization 
(Cotter et al., 1992); thus, proteolytic leavage of actin 
(Kayalar et al., 1995) and of the actin-associated protein 
fodrin (Martin et al., 1995) is likely to be relevant o these 
membrane changes. Further, the cleavage of actin by ICE 
destroys its ability to inhibit DNase I (Kayalar et al., 1995), 
which might then have effects at the level of the nucleus. 
Specific proteolytic cuts of a limited number of sub- 
strates would be repaired in the cell as the substrates are 
replaced, and unless this proteolysis outpaces the re- 
placement, we might expect the cell to survive (if such 
proteolysis is indeed central to the apoptotic process). We 
suggest, however, that this is exactly what happens, owing 
in part to the amplifying effect of the proteolytic ascade. 
Eventually, too many cuts in too many places result in a 
critical change in the cell, and it suddenly collapses into 
apoptotic death. In this scenario, the timing and exact de- 
tails of death are not "programmed" in a sequence of de- 
fined steps, but are instead set in motion like a rock slide 
(an image from the concept of criticality). In the context 
of our discussion, perhaps a better analogy is the manner 
in which a large tent collapses if lines are cut at random: 
there are fluctuations and changes in shape, but the tent 
stays up until some critical moment when everything sud- 
denly comes crashing down, a description that fits the 
process of apoptotic death. 
Life and Death: A Delicate but Robust Balance 
If ICE-like proteases are indeed components of the execu- 
tioner or are involved in its control, then, by analogy with 
p53 and other genes known to regulate apoptosis posi- 
tively, one would expect that a significant proportion of 
tumors should arise as a result of inactivation of ICE family 
proteases. By the same reasoning, crmA would be ex- 
pected to synergize with known oncogenes, such as myc, 
to transform cells. The fact that neither of these predictions 
has been fulfilled to date may simply indicate that no one 
has yet looked. Alternatively, it may be that neither crmA 
nor ICE family protease defects can contribute signifi- 
cantly to the transformed state. If this proves to be the 
case, then there are several possible explanations; the 
most obvious of these is that ICE-like proteases are not 
components of the executioner. A more interesting possi- 
bility is that loss of control over the cell death machinery 
is likely to have such disastrous consequences for a multi- 
cellular organism that mechanisms to ensure that this 
does not occur have evolved. One such mechanism may 
be redundancy, the hobgoblin of gene knockout predic- 
tions. Thus, animals lacking a functional /ce gene may 
develop normally, not because this protein is irrelevant o 
apoptosis, but because other proteases can take its place 
(Li et al., 1995; Kuida et al., 1995). 
A third scenario would be that in which all of the compo- 
nents of the executioner are required for cell growth as 
well as death. For proteases, we can readily envision the 
possibility that those that are elements of the executioner 
also process (say, at lower constitutive levels of activity) 
pro forms of proteins involved in normal cell function. 
Thus, mutations that interfere with the function of the exe- 
cutioner would simultaneously eliminate any growth ad- 
vantage a cell may obtain from losing its ability to undergo 
apoptosis. An obvious prediction that can be made from 
this scenario is that no tumor can arise as a result of inacti- 
vating mutations involving the executioner and, by exten- 
sion, that all tumors should be capable of undergoing 
apoptosis. 
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Note Added in Proof 
The biochemical purification of the active form of CPP32/YAMA 
(termed apopain) was recently described by Nicholson et al. (1995) 
(Nature 376, 37-43). In addition, another member of the ICE family, 
ICE,e~III, has been reported by Munday et al. (1995) (J. Biol. Chem. 
270, 15870-15876), as well as one, ICEr~,II, that is identical to TX/ 
ICH-2. 
